Teva Pharmaceutical Industries Limited filed a Form 8-K on November 18, 2026, disclosing that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, notified the company of his intention to resign on November 17, 2026.

Key Highlights

  • Resignation date: Dr. Eric Hughes notified Teva of his intention to resign on November 17, 2026.
  • Role affected: Dr. Hughes held the title of Executive Vice President, Global R&D and Chief Medical Officer.
  • Immediate departure: According to the filing, Dr. Hughes stepped down immediately from his role.
  • Transition period: The filing states Dr. Hughes will continue to assist with a smooth transition over the next few months.
  • Press release issued: Teva issued a press release on November 18, 2026, announcing the departure, furnished as Exhibit 99.1.

Dr. Eric Hughes Departs Teva's Global R&D Leadership

Teva Pharmaceutical Industries Limited (NYSE:TEVA) disclosed in an 8-K current report, dated November 17, 2026, and filed November 18, 2026, that Dr. Eric Hughes notified the company of his intention to resign from his position as Executive Vice President, Global R&D and Chief Medical Officer. The filing states that Dr. Hughes "will step down immediately from his role and will continue to assist with a smooth transition over the next few months."

The disclosure was made under Item 5.02 of Form 8-K, which covers the departure of directors or certain officers. No successor to the role was named in the filing. Separately, under Item 7.01, the company disclosed that it issued a press release on November 18, 2026, announcing the departure. The filing notes that the press release, furnished as Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

The 8-K was signed by Eli Kalif, Executive Vice President and Chief Financial Officer, on behalf of Teva Pharmaceutical Industries Limited. Teva is incorporated in Israel and lists its principal executive offices at 400 Interpace Parkway, #3, Parsippany, NJ 07054, according to the filing.

What Was Disclosed

Teva filed an 8-K reporting the resignation of Dr. Eric Hughes as Executive Vice President, Global R&D and Chief Medical Officer, effective immediately as of November 17, 2026, with Dr. Hughes agreeing to assist in a transition over the following months.